The use of different Peg-interferon α-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response

Journal of Viral Hepatitis

Volumn 15, Issue 4, 2008, Pages 300-304

  Napoli, N ^a,b   Giannelli, G ^b   Antonaci, A ^b   Antonaci, S ^b  

^a Section of Internal Medicine   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Chronic hepatitis C; Peginterferon 2b; Rapid virological response; Ribavirin; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 40149112319     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00944.x     Document Type: Article

References (19)

1. Liang TJ, Rehermann B, Seeff LB, Hoffnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000 132 : 296 305.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001 345 : 41 52.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 965.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
5. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
6. Giannelli G, Guadagnino G, Dentico P, Antonelli G, Antonaci S. MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004 24 : 659 663.
7. Piazzola G, Tortorella C, Schiraldi O, Antonaci S. Relationship between interferon-γ, interleukin-10 and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-α. J Clin Immunol 2000 20 : 54 61.
8. Civeira MP Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999 31 (Suppl. 1 237 243.
9. Zeuzem S, Lee JH, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 1998 27 : 1149 1156.
10. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652.
11. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002 36 (Suppl. 1 S145 S151.
12. Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol 2005 28 : 13 21.
13. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kDa)/ribavirin therapy. Hepatology 2006 43 : 954 960.
14. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol 2006 44 : 97 103.
15. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000 7 : 250 257.
16. Pawlotsky JM. Mechanisms of antiviral efficacy and failure in chronic hepatitis C. Antiviral Res 2003 59 : 1 11.
17. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003 10 : 16 22.
18. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004 39 : 880 890.
19. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004 53 : 15 18.